Overview

Adoptive SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Monocentric open phase I (dose escalation component), followed by a multi-center, randomized, phase II component benchmarking IMP+SoC against SoC
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Universitätsklinikum Köln
Collaborators:
Miltenyi Biomedicine GmbH
MMH Institute for Transfusion Medicine
ZKS Köln